Focused On-demand Library for Fidgetin-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6PIW4

UPID:

FIGL1_HUMAN

Alternative names:

Alternative UPACC:

Q6PIW4; D3DVM6; Q86V18; Q8ND59; Q9H8P1; Q9H917

Background:

Fidgetin-like protein 1 plays a crucial role in DNA repair mechanisms, specifically in DNA double-strand break repair via homologous recombination. It is uniquely recruited at sites of DNA damage independently of other key proteins in this pathway, such as BRCA2 and RAD51, in a process that requires H2AX. Beyond its involvement in DNA repair, this protein is implicated in regulating osteoblast proliferation and differentiation, as well as playing a role in male meiosis dynamics.

Therapeutic significance:

Understanding the role of Fidgetin-like protein 1 could open doors to potential therapeutic strategies, particularly in enhancing DNA repair mechanisms for conditions characterized by genomic instability. Its involvement in osteoblast proliferation and differentiation suggests potential applications in bone health and repair.